Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Merck
Johnson and Johnson
Colorcon
Express Scripts

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PERFLUTREN

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for perflutren

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00398281 ↗ Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 2006-11-01 RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
NCT00398281 ↗ Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer Completed Sidney Kimmel Cancer Center at Thomas Jefferson University Phase 3 2006-11-01 RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy.
NCT00507806 ↗ Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke Terminated ImaRx Therapeutics Phase 1/Phase 2 2005-03-01 The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity┬«]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
NCT00584402 ↗ Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation Completed University of California, Davis N/A 2007-04-01 The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas & metastases) within the liver. Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography
NCT00626873 ↗ Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary Completed National Cancer Institute (NCI) Phase 1 2007-01-01 RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer. PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.
NCT00626873 ↗ Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary Completed Icahn School of Medicine at Mount Sinai Phase 1 2007-01-01 RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer. PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.
NCT00626873 ↗ Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary Completed Vanderbilt-Ingram Cancer Center Phase 1 2007-01-01 RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer. PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for perflutren

Condition Name

Condition Name for perflutren
Intervention Trials
Breast Cancer 3
Hepatocellular Carcinoma 3
Cystic Kidney Disease 2
Chest Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for perflutren
Intervention Trials
Carcinoma 4
Breast Neoplasms 3
Carcinoma, Hepatocellular 3
Renal Insufficiency, Chronic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for perflutren

Trials by Country

Trials by Country for perflutren
Location Trials
United States 22
United Kingdom 3
India 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for perflutren
Location Trials
Pennsylvania 6
California 5
North Carolina 4
Tennessee 2
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for perflutren

Clinical Trial Phase

Clinical Trial Phase for perflutren
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 2
Phase 2 4
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for perflutren
Clinical Trial Phase Trials
Completed 13
Recruiting 4
Withdrawn 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for perflutren

Sponsor Name

Sponsor Name for perflutren
Sponsor Trials
National Cancer Institute (NCI) 6
Sidney Kimmel Cancer Center at Thomas Jefferson University 4
UNC Lineberger Comprehensive Cancer Center 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for perflutren
Sponsor Trials
Other 28
NIH 10
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Dow
Harvard Business School
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.